nelmastobart (STT-003)

P2, N=62, Recruiting, STCube, Inc.

P1/2, N=59, Active, not recruiting, Korea University Anam Hospital | Not yet recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | Trial completion date: Mar 2026 --> Dec 2026

P1/2, N=10, Terminated, STCube, Inc. | N=130 --> 10 | Trial completion date: Oct 2027 --> Aug 2025 | Recruiting --> Terminated; Company strategy

P1/2, N=52, Recruiting, STCube, Inc. | Active, not recruiting --> Recruiting

P1/2, N=52, Active, not recruiting, STCube, Inc. | Not yet recruiting --> Active, not recruiting

P1/2, N=70, Not yet recruiting, STCube, Inc.

P1, N=47, Completed, STCube, Inc. | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Feb 2024

P1/2, N=130, Recruiting, STCube, Inc. | Not yet recruiting --> Recruiting

P1, N=66, Active, not recruiting, STCube, Inc.

P1, N=66, Active, not recruiting, STCube, Inc. | Recruiting --> Active, not recruiting

The Phase 1 clinical trial of a humanized monoclonal antibody targeting BTN1A1, Nelmastorbart (hSTC810), showed no toxicity and demonstrated efficacy in multiple solid cancer patients, particularly in small cell lung cancer (SCLC)... In the current study, the application of advanced spatial biology approaches has provided valuable insights into BTN1A1's expression patterns and its role in immune regulation and evasion within the SCLC tumor microenvironment. Additionally, the development and optimization of anti-BTN1A1 antibody (Nelmastorbart) therapies should be prioritized, with a particular emphasis on understanding the factors contributing to treatment response and resistance. Furthermore, results from our current Phase I clinical trial have provided promising directions for treating small cell lung tumors.

Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.